Showing 3011-3020 of 4130 results for "".
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- FDA Greenlights First Treatment for Chronic Hand Eczema in Adultshttps://practicaldermatology.com/news/fda-approves-first-treatment-for-chronic-hand-eczema-in-adults/2475816/The US Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream, making it the first and only treatment approved for adults with moderate-to-severe chronic hand eczema (CHE) who are unresponsive to topical corticosteroids or for those unsuitabl
- Coverage Decision May Jeopardize Image-guided Skin Cancer Treatment: Reporthttps://practicaldermatology.com/news/medicare-contractors-threaten-coverage-of-noninvasive-skin-cancer-treatment/2475193/Medicare Administrative Contractors (MACs) are proposing to withdraw insurance coverage for image-guided superficial radiation therapy (IGSRT), according to a news letter from SkinCure Oncology. IGSRT is an FDA-cleared, nonin
- Biologics, JAKs, and More Cited as Potential Treatments for CPUOhttps://practicaldermatology.com/news/Biologics-JAKis-More-Cited-Potential-Treatments-CPUO/2471552/New therapies for chronic pruritus of unknown origin (CPUO) could be close, Gil Yosipovitch, MD, said during his presentation, “What’s Best and What’s Next for Systemic Itch and CPUO” at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. “These are patients
- FDA Greenlights BIMZELX for Chronic Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-greenlights-bimzelx-chronic-hidradenitis-suppurativa/2468635/The Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). According to a press release f
- Analysis: Higher Infection and Acne Risks with JAK Inhibitors in ADhttps://practicaldermatology.com/news/analysis-higher-infection-and-acne-risks-jak-inhibitors-ad/2468381/Researchers for a new analysis have provided a data and analytics framework for the evaluation of the safety of immune-modulating drugs (IMDs) in treating atopic dermatitis (AD). The study authors designed the system to generate timely, high-quality evidence using sequential propensity sco
- Practical Dermatology Joins the ReachMD Network to Expand Audiences, Channels, and Content Syndicationhttps://practicaldermatology.com/news/practical-dermatology-joins-reachmd-network-expand-audiences-channels-and-content-syndication/2467450/Practical Dermatology today announced its partnership with ReachMD to syndicate its vast content library across all channels of the ReachMD Network, which includes websites, mobile apps, email newsletters, social channels, live events, radio stations, social me
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At
- Updated AAD Guidelines on AD in Adults Back Use of Biologics, JAK Inhibitorshttps://practicaldermatology.com/news/updated-aad-guidelines-on-ad-in-adults-back-use-of-biologics-jak-inhibitors/2462123/Updated American Academy of Dermatology (AAD) guidelines on systemic treatment of atopic dermatitis (AD) in adults strongly back the use of dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib. “When the last guidelines were published in 2014, only no
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide